Download presentation
Presentation is loading. Please wait.
Published byBrent Cunningham Modified over 7 years ago
1
UCB Immunology Patient Value Unit November 2015
2
An international executive team
Iris Löw-Friedrich Development and Medical Ismail Kola New Medicines Emmanuel Caeymaex Immunology Jeff Wren Neurology Jean-Christophe Tellier CEO Detlef Thielgen Finance Fabrice Enderlin Talent & Company Reputation Anna Richo Legal Mark McDade Patient Value Operations Bharat Tewarie Strategic Marketing
4
What UCB stands for
5
UCB, the right size biopharma partner Focusing on treating patients with severe diseases in Neurology, Immunology, Bone A “Right-Sized”(1) Biopharma company €3.3 billion revenues in 2014 Strong investment in R&D (~25% of revenue) Global footprint, with operations in ~40 countries ~8,500 employees Euronext listed (1) your product will reach patients in all key markets and get the attention it deserves, including from our senior leadership
6
3 core medicines for patients with severe diseases
Rheumatoid arthritis psoriatic arthritis (PSA) ankylosing spondylitis (AS) – US axial spondyloarthritis (AxSpA) – EU Crohn’s disease Epilepsy adjunctive therapy Parkinson’s disease Restless legs syndrome
7
Other key products Keppra® (levetiracetam)
Epilepsy adjunctive therapy (also in monotherapy in Europe) – Sold as E Keppra® in Japan Keppra XR® (levetiracetam – Extended-release tablets) – U.S. only Epilepsy adjunctive therapy Zyrtec® (cetirizine HCl) Seasonal allergic rhinitis Xyzal® (levocetirizine dihydrochloride) Allergies and chronic idiopatic urticaria
8
Moving forward - seeking additional R&D partnerships
Phase 1 Phase 2 Phase 3 romosozumab(1) osteoporosis - postmenopausal women Phase 3 results: H1 2016 osteoporosis – men Phase 3 results: H2 2016 UCB0942 (PPSI) highly drug resistant epilepsy Phase 2 results: Q4 2016 bimekizumab / UCB4940 (IL17AF) psoriatic arthritis Phase 2a results: H2 2015 bimekizumab & Cimzia® combo rheumatoid arthritis Phase 2a results: H1 2017 UCB5857 (PI3K Delta inhibitor) immune-inflammatory diseases Phase 2 start: H2 2015 dapirolizumab pegol (CD40L antibody)(2) systemic lupus erythematosus Phase 2 start: 2016 UCB7665 immunological diseases UCB4144 / VR942(3) asthma neurology immunology bone (1) partner: Amgen (2) partner: Biogen (3) partner: Vectura
9
Cutting-edge research and science
Addressing unmet patient needs and delivering breakthrough medicines Two main Research Centers World-class expertise in selected therapeutic areas and disease mechanisms Connecting science in new ways - chemistry (small, chemically-derived molecules) and biology (large antibody-based molecules), to leverage the potential of these two disciplines ‘Open innovation’ model based on strong partnerships with other biotech companies and prominent universities Biologics pilot plant – Braine-l’Alleud, Belgium Biologics R&D centre - Slough, U.K. Two main Research Centers
10
Where can you be sure an asset will deliver transformational Benefit?
Pre-clinical Phase 1 Phase 2 Phase 3 Cost Increase Decisions Get More Difficult (Emotional/Financial)
11
Partnering in Immunology - leveraging respective strengths in research, development and commercial capabilities 2015 Development & Commercial Cimzia in PsO 2014 Research & Development Peptide combination to address high unmet need in Type 1 Diabetes 2012 Research collaboration Exploring the microbiome Selected partnerships in Neurology
12
Everything we do starts with a simple question: “How will this make a difference to the lives of people with severe diseases?” 12
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.